Centro de Esclerosis Múltiple de Buenos Aires (CEMBA), Buenos Aires, Argentina.
Servicio de Neurología, Hospital Universitario de CEMIC, Buenos Aires, Argentina.
J Neurovirol. 2021 Oct;27(5):750-754. doi: 10.1007/s13365-021-01011-w. Epub 2021 Sep 29.
The objective of the present study was to identify the frequency of MS patients in Latin America (LATAM) that received the influenza vaccine during the most recent season and the reasons related to non-vaccination. Cross-sectional study between November and December 2020 in a large cohort of MS patients from LATAM. Patients responded about recommendation of receiving influenza vaccine and the use of it as well as reasons for not using the vaccine. Four hundred twelve MS patients were included in the analysis. 47.3% of patients were recommended to receive the vaccine from the treating physician. Nearly 54% of patients did not receive the influenza vaccine, and the most frequent cause was that it was neither recommended nor mentioned by the treating physician (27.4%). Female gender (OR = 2.3, 95%CI 1.4-3.8, p = 0.001) was associated with an increased risk of recommendation, while a progressive form of MS and higher EDSS decreased the risk (OR = 0.49, 95%CI 0.27-0.90, p = 0.023; OR = 0.65, 95%CI 0.55-0.97, p = 0.02, respectively). Despite the evidence to recommend the influenza vaccine in MS patients, a limited number of patients in clinical practice received such recommendation.
本研究的目的是确定拉丁美洲 (LATAM) 最近一个流感季节接受流感疫苗的多发性硬化症 (MS) 患者的频率，以及与未接种疫苗相关的原因。这是一项在 LATAM 进行的大型 MS 患者队列的横断面研究，于 2020 年 11 月至 12 月间进行。患者对接受流感疫苗的建议以及对疫苗的使用情况和不使用疫苗的原因进行了回答。分析共纳入 412 名 MS 患者。47.3%的患者被其治疗医生建议接种疫苗。近 54%的患者未接种流感疫苗，最常见的原因是治疗医生未建议或未提及接种疫苗（27.4%）。女性（OR=2.3，95%CI 1.4-3.8，p=0.001）与较高的推荐风险相关，而 MS 的进行性形式和较高的 EDSS 降低了这种风险（OR=0.49，95%CI 0.27-0.90，p=0.023；OR=0.65，95%CI 0.55-0.97，p=0.02，分别）。尽管有证据表明建议 MS 患者接种流感疫苗，但在临床实践中，只有少数患者接受了此类建议。
